Vantage logo

Approaching datasets for big pharma

J&J moves FcRn towards a big new therapy area, while Bristol, Merck, Astrazeneca and Daiichi Sankyo await important oncology catalysts. 

Vantage logo

Nkarta goes back to basics

After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.